脑转移瘤的放射治疗:美国放射肿瘤学会(ASTRO)临床实践指南
该指南由美国放射肿瘤学会(ASTRO)召集工作组,基于医疗保健研究与质量局(AHRQ)的系统综述,针对非血液系统实体瘤脑转移(完整或术后)的放射治疗管理提出推荐。强烈推荐对有限脑转移且ECOG评分0-2的患者行立体定向放射外科(SRS);对术后脑转移强烈推荐SRS以提高局部控制;对预后良好且接受全脑放疗者强烈推荐海马保护与美金刚;对预后差者强烈推荐早期引入姑息治疗。
要点
- 有限脑转移且ECOG 0-2的患者强烈推荐立体定向放射外科(SRS)。
- 术后脑转移强烈推荐SRS以改善局部控制。
- 预后良好且接受全脑放疗者强烈推荐海马保护与美金刚。
核心结论
- 工作组提出推荐以指导脑转移瘤放射治疗的最佳临床实践,并强烈强调多学科照护。
研究设计与样本
- 美国放射肿瘤学会(ASTRO)召集工作组,基于医疗保健研究与质量局(AHRQ)提供的系统综述,采用预定义的共识建立方法与证据质量及推荐强度分级系统制定推荐。
主要发现
- 对有限脑转移且东部肿瘤协作组(ECOG)体力状态0-2的患者强烈推荐SRS。
- 对引起占位效应和/或大于4 cm的所有肿瘤,条件性推荐与神经外科多学科讨论以考虑手术切除。
- 对有症状脑转移患者强烈推荐 upfront 局部治疗。
- 对适合中枢神经系统活性系统治疗的无症状脑转移患者,条件性推荐通过多学科和以患者为中心的决策来确定局部治疗是否可安全延迟。
- 对术后脑转移患者强烈推荐SRS以改善局部控制。
关键数值与推荐
- 对预后良好且接受全脑放疗的脑转移患者强烈推荐海马保护与美金刚。
- 对预后差的患者强烈推荐早期引入姑息治疗以管理症状和支持照护者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline provides updated evidence-based recommendations addressing recent developments in the management of patients with brain metastases, including advanced radiation therapy techniques such as stereotactic radiosurgery (SRS) and hippocampal avoidance whole brain radiation therapy and the emergence of systemic therapies with central nervous system activity. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the radiotherapeutic management of intact and resected brain metastases from nonhematologic solid tumors. The guideline is based on a systematic review provided by the Agency for Healthcare Research and Quality. Recommendations were created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS: Strong recommendations are made for SRS for patients with limited brain metastases and Eastern Cooperative Oncology Group performance status 0 to 2. Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for all tumors causing mass effect and/or that are greater than 4 cm. For patients with symptomatic brain metastases, upfront local therapy is strongly recommended. For patients with asymptomatic brain metastases eligible for central nervous system-active systemic therapy, multidisciplinary and patient-centered decision-making to determine whether local therapy may be safely deferred is conditionally recommended. For patients with resected brain metastases, SRS is strongly recommended to improve local control. For patients with favorable prognosis and brain metastases receiving whole brain radiation therapy, hippocampal avoidance and memantine are strongly recommended. For patients with poor prognosis, early introduction of palliative care for symptom management and caregiver support are strongly recommended. CONCLUSIONS: The task force has proposed recommendations to inform best clinical practices on the use of radiation therapy for brain metastases with strong emphasis on multidisciplinary care.
引用
- Gondi V, Bauman G, Bradfield L, et al. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022. PMID: 35534352. doi:10.1016/j.prro.2022.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。